gcn2 activator dcc-2812
Generic: GCN2 Activator DCC-2812
gcn2 activator dcc-2812: 1 clinical trial tracked.
gcn2 activator dcc-2812 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about gcn2 activator dcc-2812, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Primary endpoint: Number of Participants with Dose-limiting Toxicities (DLTs)
Interventionalopen60 targetStarted 2025-08Completion 2029-025 sites · United StatesDeciphera Pharmaceuticals, LLC